INTRODUCTION
The androgen receptor (AR) mediates androgen functions in the differentiation and maturation of the male reproductive organs and in the development of male secondary sex characteristics (1) . Mutations in the AR gene are associated with the androgen insensitivity syndrome (AIS) (2, 3) . Numerous somatic mutations in the AR gene have been reported among prostate cancer patients and as well as in prostate cancer cell lines and xenografts (3, 4) . Most of these mutations have been detected in tumor tissues of late-stage prostate carcinoma, indicating that somatic mutation of the AR gene might be involved in the progression and aggressiveness of prostate cancer.
The AR is a member of the nuclear receptor (NR) superfamily (5) . These receptors are characterized by distinct functional domains: an N-terminal part, involved in ligandindependent transcription activation (AF1), a DNA-binding domain (DBD), and a C-terminal part (LBD) involved in ligand binding and ligand-dependent transcription activation (AF2) (6) .
As for other steroid receptors, ligand binding is generally believed to result in a conformational charge in AR with consequent dissociation of heat shock proteins/chaperones (7), dimerization and binding to cognate androgen response elements (AREs) in target genes, and, (through its AF1 and AF2 domains) interactions with various coactivators that facilitate transcription by the general transcriptional machinery (8) . The DBD encompasses two Zn-finger-like modules and binds as dimers to two hexameric sequences orientated as direct or inverted repeats (9, 10) .
Although the DBD and LBD of steroid hormone receptors are highly conserved, there is much less homology among steroid hormone receptors in their N-terminal parts. The AR has a long N-terminal part with a strong autonomous AF1 and interacts directly with AF2 in the C-terminal part (11, 12) . The N-and C-terminal interactions are important for androgen-induced gene 4 regulation, and disruption of these interactions may be linked to AIS (13, 14) . The conserved FXXLF and WXXLF motifs within the N-terminal part seam to be involved in pairwise interactions between AF1 and AF2 (15) . The N-terminal part contains stretches of glutamines (coded by CAG) and glycine (coded by GGN) (16) . Expansion of the CAG repeats is associated with X-linked spinal and bulbar muscule atrophy (17) . A shorter CAG repeat is associated with an increased transactivation of AR (18, 19) , but the biological role of GGN repeats is less clear.
In this study, we demonstrated that AR contains a highly conserved inhibitory domain within the N-terminal region. The inhibitory domain interacted directly with DBD and inhibited
EXPERIMENTAL PROCEDURES
Production and Purification of Recombinant Proteins -The human full-length AR was expressed in Sf9 cells via the baculovirus expression vector pVL1393 (Pharmingen), and the recombinant AR was purified as described (20) . All AR and GR cDNA fragments were amplified by PCR with specific oligonucleotides, cut with NdeI and BamHI, and subsequently cloned in the corresponding restriction sites of the vectors pET15d (Novagene), pGEX-2TL (Pharmacia), and pcDNA3.1 (Invitrogen). The fragments were expressed as 6His-tagged (via pET15d) or GST-fusion (via pGEX-2TL) proteins in E. coli BL21 and purified through NTA Ni 2+ agarose or glutathione Sepharose columns, respectively. Point mutations were generated by using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's instructions and confirmed by DNA sequencing analysis. The mutated proteins were expressed and purified similarly. (21) . However, the AR-DNA interactions have not been studied with the highly purified recombinant AR. To this end, the FLAG epitope-tagged human AR was expressed in Sf9 cells and immuno-purified under high salt conditions (500 mM KCl) to strip off heat shock proteins associated with the unliganded AR.
Gel Shift Assay -
The recombinant AR preparation is near homogeneity ( to the binding reaction that contained the fixed amount (0.3 pmol) of AR537-644, the density of the DBD-ARE complex dramatically decreased (Fig. 2C, lanes 3-8) . These results indicate that AR477-538 specifically inhibits the DBD-ARE interactions in trans as well as in cis. We noticed that different preparations of AR477-538 contained various amounts of the full-length protein and that amounts of the full-length protein (Fig. 2B , lane 1, indicated by the top arrow on the right) were correlated with the inhibition ability of AR477-538. As negative controls, the recombinant PAR-4 (26), TIP30 (27) and RPC39 (28) expressed and purified similarly did not significantly affect the DBD binding to the ARE probe (Fig. 2D) .
The Inhibitory Domain Interacts with DBD and Inhibits AR Transactivation -The
protein-protein pull-down assay was performed to investigate whether the inhibitory domain (ID)
interacts directly with DBD. GST and GST-DBD(AR537-644)-fusion protein were expressed in bacteria and immobilized on glutathione Sepharose beads (Fig. 3A, lanes 2 and 3) . The in vitro Coexpression of AR477-558 did not influence reporter gene activity driven by p53, indicating that the inhibiting effect of AR477-558 was specific for AR. Western blot analysis revealed that the AR protein levels in the absence and presence of AR477-558 were comparable (Fig. 3C , lane 3 versus lane 2). On the basis of in vitro studies (Fig. 2) , the ID inhibited AR transactivation, most likely by blocking the interaction of the AR with the ARE.
The Inhibitory Domain Is Specific for AR -
The DNA-binding domains of AR, glucocorticoid receptor (GR), progesterone receptor (PR), and mineralocorticoid receptor (MR) are highly conserved (29) . Not surprisingly, they bind to the same consensus DNA site (GGTACAnnnTGTTCT) and can be considered a subfamily of the NR superfamily. However, the inhibitory domain of AR is not conserved in the other receptors (Fig. 4A ). GR418-525 and GR358-525 were expressed and purified (Fig. 4B, lanes 1 and 2) . Gel shift assay demonstrated that GR358-525 and GR418-525 bound the ARE probe similarly (Fig. 4C , lane 3 versus lane 2).
The lower band (Fig. 4C, lane 3 , indicated by a star on the right) might contain a monomer of GR358-525. These results indicated that the ID in AR is not conserved in GR, and thus the inhibitory domain is specific for AR.
Mutations in the ID Enhance AR Transactivation -Sequence alignment shows that the ID of AR is highly conserved through evolution (Fig. 5A) . To further characterize the biological effects of this region, we mutated two conserved residues (K520 and R538) in the ID and cDNAs encoding the mutated AR (K520E and R538E) were transient transfected in PC3 cells with the luciferase reporter plasmid. The mutated AR had elevated transactivation activity compared with the wild-type AR (Fig. 5B) , although the mutated and wild-type AR were expressed at the same level in the transfected cells (Fig. 5C, lanes 2-4) . The ID (AR477-558) from the mutated AR (K520E and R538E) were expressed and purified (Fig. 2B, lanes 2 and 3) . The gel shift assay revealed that mutations of K520E and R538E decreased the inhibitory ability of ID (Fig.   5D , lanes 9-12 and 13-16 versus lanes 5-8). Ten nanograms of the wild-type AR477-558 almost completely blocked AR537-644 binding to the ARE probe (Fig. 5D) . However, the same amount of the mutated (K520E and R538E) AR477-558 inhibited the DBD-ARE interaction only 65% and 35%, respectively (Fig. 5D) . Thus, enhancement of AR transactivation by mutations of K520E and R538E correlates with a decrease in the inhibitory effect of ID on DBD-ARE interactions.
DISCUSSION
The N-terminal parts of NRs are the most divergent among members of this superfamily of proteins, suggesting that each receptor will take on a unique N-terminal conformation to determine its specificity. This paper describes a highly conserved novel inhibitory domain, designated ID, which lies in the N-terminal 81-amino acid residues upstream of the DBD of AR.
ID interacts directly with DBD and strongly inhibits the DBD-ARE interactions in vitro and AR transactivation in vivo.
Much of the work devoted to understanding regulation of transcription by the AR has Another study has demonstrated that mutations on 668 QPIF 671 at the boundary of the hinge and ligand-binding domain of AR, resulting in receptors that exhibit 2-to 4-fold increased activity compared with the wild-type AR in response to dihydrotestosterone, and these mutations have been detected in prostate cancer patients (36) . However, the molecular mechanism for this phenomenon is unclear.
Several mutations found in men with prostate cancer (37) and in men with the AIS (38,39) localize in ID (Fig. 5A ). These mutations might change the function of ID, therefore affecting AR transactivation. D528G mutation was detected in a patient with prostate cancer (37) and we found that AR with D528G mutation was more active (>3-fold) than the wild-type AR in transient transfection assays (data not shown). However, this mutation enhanced the stability of AR in PC3 cells (data not shown). Currently, we are investigating whether the enhanced AR transactivation is due to the enhanced AR stability, the decreased ID function, or both. Thus, ID may play an important regulatory role in AR function, and dysfunction of ID may contribute to prostate cancer or AIS in some men. 
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